Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Other Accumulated Expenses (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Other Accumulated Expenses for 12 consecutive years, with $341000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Accumulated Expenses rose 16.78% year-over-year to $341000.0, compared with a TTM value of $341000.0 through Sep 2025, up 16.78%, and an annual FY2024 reading of $490000.0, up 56.05% over the prior year.
  • Other Accumulated Expenses was $341000.0 for Q3 2025 at CytomX Therapeutics, up from $111000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $943000.0 in Q1 2022 and bottomed at $63000.0 in Q1 2025.
  • Average Other Accumulated Expenses over 5 years is $403526.3, with a median of $341000.0 recorded in 2025.
  • The sharpest move saw Other Accumulated Expenses surged 601.52% in 2021, then crashed 86.15% in 2025.
  • Year by year, Other Accumulated Expenses stood at $713000.0 in 2021, then plummeted by 63.39% to $261000.0 in 2022, then rose by 20.31% to $314000.0 in 2023, then soared by 56.05% to $490000.0 in 2024, then crashed by 30.41% to $341000.0 in 2025.
  • Business Quant data shows Other Accumulated Expenses for CTMX at $341000.0 in Q3 2025, $111000.0 in Q2 2025, and $63000.0 in Q1 2025.